A recent study studied the therapeutic potential of targeting c-Jun N-terminal kinase-2 (Jnk2) in chronic liver disease (CLD) and end-stage liver cancer [88]. This evidence concerns the gene MAPK9 and congenital secretory chloride diarrhea 1.